The CIMT Regulatory Research Group (RRG) was founded in 2008. It incorporates members from academia, biotech industries and regulatory authorities such as PEI. It is aiming to facilitate the translation of scientific knowledge from bench to bedside.
RRG’s main goals:
RRG’s main goals:
- identification of regulatory challenges posed by emerging immunotherapies.
- development of new regulatory concepts to facilitate clinical testing of innovative immunotherapies.
- facilitating discussion between all groups relevant for the translation of scientific knowledge into the hospital.
